ClinicalTrials.gg

Program

Aticaprant

Also written as “JNJ-67953964”, “14C-aticaprant” and “Aticaprant Supratherapeutic Dose”.

Its studies are mostly in Depressive Disorder, Major · Schizophrenia · Smoking · Alcoholism, led by 2 companies.

Furthest: phase 3, since Jul 10, 202213 company-led studies, 1 open or runningNext primary completion: Jun 21, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson121 open or runningphase 3since Jul 10, 2022Dec 15, 2015Jun 21, 2027phase 1 · NCT07615426
Eli Lilly10 open or runningphase 1since Oct 20, 2010Oct 20, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2010First study: phase 1 study in AlcoholismNew to Eli LillyEli Lilly · NCT01232439 · 13 enrolled · United States
  2. Dec 15, 2015Johnson & Johnson's first study: phase 2 study in SmokingNew to Johnson & JohnsonJohnson & Johnson · NCT02641028 · 71 enrolled · United States
  3. Jun 6, 2018Phase 2 study in Depressive Disorder, MajorJohnson & Johnson · NCT03559192 · 181 enrolled · United States, Germany, Moldova, Republic of and more
  4. Dec 2, 2019Phase 1 study in HealthyJohnson & Johnson · NCT04185051 · 76 enrolled · Belgium
  5. Mar 9, 2021Phase 1 study in HealthyJohnson & Johnson · NCT04791332 · 30 enrolled · Japan
  6. Jan 17, 2022Phase 1 study in HealthyJohnson & Johnson · NCT05197062 · 8 enrolled · Netherlands
  7. May 20, 2022Phase 1 study in HealthyJohnson & Johnson · NCT05387759 · 60 enrolled · Belgium
  8. Jul 10, 2022Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT05455684 · 513 enrolled · United States, Argentina, Australia and more
  9. Aug 25, 2022Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT05518149 · 871 enrolled · United States, Argentina, Australia and more
  10. Sep 20, 2022Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT05550532 · 444 enrolled · United States, Argentina, Brazil and more
  11. Jul 17, 2024Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT06514742 · 101 enrolled · United States, Belgium, Brazil and more
  12. Oct 9, 2024Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT06635135 · 47 enrolled · United States, Argentina, Belgium and more
  13. May 22, 2026Phase 1 study in SchizophreniaJohnson & Johnson · NCT07615426 · 64 planned · United States

Ahead

  1. Jun 21, 2027Primary completion: phase 1 study in SchizophreniaJohnson & Johnson · NCT07615426

TargetBeta

OPRK1 →read by rule
“Kappa opioid receptor antagonist”ChEMBL 37, by rule

Other programs on OPRK1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
cebranopadolruleTris Pharmaphase 318
nalfurafineruletoray-industries-incphase 39
asimadolineruletioga-pharmaceuticalsphase 36
icalcaprantAbbViephase 26

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07615426Schizophrenia · United States1RecruitingJohnson & JohnsonJun 21, 202764
NCT06635135Depressive Disorder, Major · United States, Argentina, Belgium and more3TerminatedJohnson & JohnsonApr 9, 202547
NCT06514742Depressive Disorder, Major · United States, Belgium, Brazil and more3TerminatedJohnson & JohnsonApr 8, 2025101
NCT05550532Depressive Disorder, Major · United States, Argentina, Brazil and more3CompletedJohnson & JohnsonNov 8, 2024444
NCT05518149Depressive Disorder, Major · United States, Argentina, Australia and more3TerminatedJohnson & JohnsonApr 25, 2025871
NCT05455684Depressive Disorder, Major · United States, Argentina, Australia and more3CompletedJohnson & JohnsonSep 18, 2024513
NCT05387759Healthy · Belgium1CompletedJohnson & JohnsonOct 4, 202260
NCT05197062Healthy · Netherlands1CompletedJohnson & JohnsonMar 2, 20228
NCT04791332Healthy · Japan1CompletedJohnson & JohnsonJul 28, 202130
NCT04185051Healthy · Belgium1CompletedJohnson & JohnsonApr 21, 202176
NCT03559192Depressive Disorder, Major · United States, Germany, Moldova, Republic of and more2CompletedJohnson & JohnsonMay 6, 2020181
NCT02641028Smoking · United States2CompletedJohnson & JohnsonSep 13, 201671
NCT01232439Alcoholism · United States1CompletedEli LillyApr 201113

How it is read

Names in the registry

  • “Aticaprant”, 6 entries
  • “JNJ-67953964”, 3 entries
  • “14C-aticaprant”, 1 entry
  • “Aticaprant Supratherapeutic Dose”, 1 entry
  • “Aticaprant Therapeutic Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.